Market Place
Sourcing Support
TScan Therapeutics Announces $30M Offering at 37% Premium
26 Dec 2024 //
GLOBENEWSWIRE
TScan Refinances Debt with 52.5M Loan from Silicon Valley Bank
23 Dec 2024 //
GLOBENEWSWIRE
TScan Therapeutics Presents Updated ALLOHA™ Trial Data at ASH 2024
09 Dec 2024 //
GLOBENEWSWIRE
TScan Named Top Place to Work by Boston Globe for 3 Years
05 Dec 2024 //
GLOBENEWSWIRE
TScan Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
TScan Therapeutics Presents Data from ALLOHA™ Phase 1 Trial
05 Nov 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Presentations At SITC Annual Meet
04 Oct 2024 //
GLOBENEWSWIRE
TScan Therapeutics to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
TScan Therapeutics Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Updates to its Board of Directors
14 Jun 2024 //
GLOBENEWSWIRE
TScan At Upcoming Jefferies Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
TScan Gets FDA RMAT For Lead TCR-T Candidates In Heme Malignancies
29 May 2024 //
GLOBENEWSWIRE
TScan Therapeutics Reports Q1 2024 Results, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
TScan First Patient Dosed In Solid Tumor TCR-T Trial
09 May 2024 //
GLOBENEWSWIRE
TScan Announces Underwriters` Option Exercise
24 Apr 2024 //
GLOBENEWSWIRE
TScan to Present at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
TScan To Present At ASGCT 2024 Annual Meeting
22 Apr 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Closing of Upsized Public Offering
19 Apr 2024 //
GLOBENEWSWIRE
TScan Provides Clinical Pipeline Update, Highlights Near-Term Priorities
16 Apr 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
16 Apr 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
16 Apr 2024 //
GLOBENEWSWIRE
Tscan Appoints Seasoned Hematology and Oncology Expert Louis as CMO
08 Apr 2024 //
GLOBENEWSWIRE
TScan Announces Upcoming Presentation at the Needham Virtual Health Conference
02 Apr 2024 //
GLOBENEWSWIRE
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
TScan to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
TScan Therapeutics Presents Promising Phase 1 Results on TSC-100 and TSC-101
26 Feb 2024 //
GLOBENEWSWIRE
TScan to Discuss Results from Phase 1 Heme Malignancies Study Presented
14 Feb 2024 //
GLOBENEWSWIRE
TScan Therapeutics Appointed Dawn Pinchasik as Vice President
06 Feb 2024 //
GLOBENEWSWIRE
TScan Appoints Seasoned Industry Executive Jason A. Amello as CFO
29 Jan 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces Best Abstracts Award
18 Jan 2024 //
GLOBENEWSWIRE
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
04 Jan 2024 //
GLOBENEWSWIRE
TScan Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101
09 Dec 2023 //
GLOBENEWSWIRE
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors
07 Dec 2023 //
GLOBENEWSWIRE
TScan Therapeutics Appointed Justin McCue, Ph.D., as Chief Technology Officer
04 Dec 2023 //
GLOBENEWSWIRE
TScan Therapeutics to Host Virtual KOL Event
04 Dec 2023 //
GLOBENEWSWIRE
TScan Named Top Place to Work by The Boston Globe for Two Consecutive Years
30 Nov 2023 //
PRESS RELEASE
TScan Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program
06 Nov 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces Upcoming Presentation at the 65th Annual Meeting
02 Nov 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces Upcoming Presentations at Annual Meeting
27 Sep 2023 //
GLOBENEWSWIRE
TScan Therapeutics to Participate in Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Tscan Announces FDA Clearance of Invg NDA for TSC-203-A0201 Targeting PRAME
29 Aug 2023 //
GLOBENEWSWIRE
TScan Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Longwood launches startup Solu with drug candidates from GSK and $31M to start
01 Aug 2023 //
ENDPTS
Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
06 Jul 2023 //
BUSINESSWIRE
TScan Therapeutics Announces Transition of Chief Financial Officer
29 Jun 2023 //
GLOBENEWSWIRE
TScan Announces FDA Clearance of Investigational NDA for TSC-200-A0201
06 Jun 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces Closing of Public Offering
01 Jun 2023 //
PRESS RELEASE
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces Pricing of $140 Million Public Offering
26 May 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces Launch of Proposed Public Offering
25 May 2023 //
GLOBENEWSWIRE
TScan Appoints Gavin MacBeath, Ph.D. as CEO and as a Member of the BOD
24 May 2023 //
GLOBENEWSWIRE
TScan Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101
17 May 2023 //
GLOBENEWSWIRE
TScan Therapeutics Reports 1Q 2023FYR &Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
Amgen enlists TScan to work on Crohn`s in deal potentially worth $500M+
10 May 2023 //
ENDPTS
Amgen & TScan Announce Collab to Identify Novel Targets in Crohn™s Disease
09 May 2023 //
GLOBENEWSWIRE
TScan Announces Upcoming Trial in Progress Poster Presentation at the ASGCT
02 May 2023 //
GLOBENEWSWIRE
TScan Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
10 Apr 2023 //
GLOBENEWSWIRE
TScan Therapeutics Announces CEO Transition
31 Mar 2023 //
GLOBENEWSWIRE
